Allogeneic ATA 188

Drug Profile

Allogeneic ATA 188

Alternative Names: Allogeneic EBV-directed T-cell therapy; EBV-CTLs; EBV-targeted T-cell; Epstein-Barr Virus-directed cytotoxic T lymphocytes

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Atara Biotherapeutics
  • Class T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple sclerosis
  • Preclinical Solid tumours

Most Recent Events

  • 27 Oct 2017 Preclinical trials in Solid tumours in USA (unspecified route) (Atara Biotherapeutics pipeline, October 2017)
  • 19 Oct 2017 Phase-I clinical trials in Multiple sclerosis (Treatment-experienced) in Australia (IV) (NCT03283826)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top